Previous close | 0.4450 |
Open | 0.4450 |
Bid | 0.4400 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.4400 - 0.4550 |
52-week range | 0.2400 - 0.4850 |
Volume | |
Avg. volume | 1,223,220 |
Market cap | N/A |
Beta (5Y monthly) | 1.79 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxelOngoing complete response has been maintained since the patient started treatment with efti monotherapyEfti + paclitaxel combination continues to be well tolerated with a favourable safety profileFirst-ever 90mg dosing leads to higher maximum concentration of efti, as well as pharmacologically active level u
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with standard therapiesSoft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical needAdditional data from EFTISARC-NEO planned for a medical confe
Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patient reporting a complete response (complete disappearance of all lesions), and a 100% disease control rateSubsequent to quarter end announced a positive preliminary response rate of 26.9% in first line metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expressionPreclinical stu